Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness

Rhea-AI Summary

Opus Genetics (Nasdaq: IRD) was featured on Good Morning America on Nov 3, 2025 for its investigational gene therapy OPGx-LCA5 targeting LCA5-related inherited retinal disease. The segment highlighted participant Lindsey Rambo and described the therapy's approach of delivering a functional LCA5 gene to retinal cells to restore photoreceptor function and partial vision.

The story coincides with ongoing Phase 1/2 trials, multiple active clinical programs for LCA5 and BEST1, a newly activated site at the Retina Foundation of the Southwest, and support from RD Fund and Foundation Fighting Blindness.

Insights

Clinical and Investor Communications Analyst

National media feature raises visibility for Opus Genetics and highlights early clinical signs of restored vision in an ongoing Phase 1/2 trial.

Opus Genetics gained broad public visibility on Good Morning America on Nov. 03, 2025, spotlighting a participant in its Phase 1/2 trial of OPGx-LCA5 and describing partial restoration of sight. Media exposure amplifies awareness of the company’s clinical program, may aid patient recruitment, and can strengthen relationships with existing funders named in the release.

The announcement’s business mechanism is reputational and operational: human-interest coverage can lower recruitment friction and increase nonprofit and physician engagement, but it does not itself change clinical endpoints or regulatory status. Key dependencies include continued favorable safety and efficacy data from the LCA5 trial and progress at newly activated clinical sites; risks include the usual uncertainty of early-stage trials and the gap between anecdotal patient outcomes and statistically robust results.

Watchables in the near term are further trial data releases, formal efficacy results from the Phase 1/2 program, and additional site activations or enrollment milestones expected over the coming months. Media attention is a positive signal for community momentum, but its material impact hinges on forthcoming clinical readouts and regulatory milestones.

RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs), announced today that its pioneering work was featured on Good Morning America (ABC News) in honor of World Blindness Awareness Month.

The national feature highlighted the story of Lindsey Rambo, the second participant in Opus Genetics’ ongoing Phase 1/2 trial of gene therapy OPGx-LCA5, aimed at restoring vision for people living with a rare genetic form of blindness caused by mutations in the LCA5 gene, which encodes lebercilin, a protein essential for photoreceptor structure.

The GMA segment, titled “Gene therapy offers hope for blindness,” explores how Opus Genetics’ investigational gene therapy is helping individuals born blind regain partial sight, an unprecedented step forward for the IRD community. The story brings national attention to the life-changing potential of gene therapy and the scientists and patients driving progress in the fight against inherited blindness.

“We are deeply honored to have Opus Genetics and Lindsey’s story featured on Good Morning America,” said George Magrath, M.D., Chief Executive Officer of Opus Genetics. “For the millions affected by inherited retinal diseases, these advancements represent hope. Our mission has always been to strive to bring the most promising gene therapies from the lab to patients as quickly and safely as possible.”

“Taking part in this study has given me hope not just for myself, but for people living with inherited blindness,” said Lindsey Rambo, the second participant in the Opus Genetics LCA5 clinical trial. “Being featured on Good Morning America and sharing my experience means helping others understand that research like this can potentially change lives.”

By delivering a functional copy of the defective gene directly to retinal cells, Opus Genetics’ approach aims to restore the function of light-sensing photoreceptors and, ultimately, vision itself.

The gene therapy featured on Good Morning America was made possible by Opus Genetics, with support from the Retinal Degeneration (RD) Fund and the Foundation Fighting Blindness.

The GMA feature coincides with Opus Genetics’ growing clinical and community momentum, including multiple ongoing trials for LCA5 and BEST1 gene therapies, a newly activated site at the Retina Foundation of the Southwest.

Watch the full Good Morning America feature here: https://www.goodmorningamerica.com/video/127055565

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, expectations regarding us, our business prospects and our results of operations and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, and our other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “strive”, “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise.

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. Opus Genetics’ pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy candidates are OPGx-LCA5, which is in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, a partnered therapy currently approved in one indication and being studied in two Phase 3 programs for presbyopia and reduced low light vision and nighttime visual disturbances. Opus Genetics is based in Research Triangle Park, NC. For more information, please visit www.opusgtx.com.

Contacts:

Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Source: Opus Genetics, Inc.

FAQ

What did Opus Genetics (IRD) announce on Good Morning America on Nov 3, 2025?

Opus Genetics was featured for its investigational gene therapy OPGx-LCA5 and a patient story showing partial vision restoration in a Phase 1/2 trial.

What is OPGx-LCA5 and how does it work in Opus Genetics' IRD trial (IRD)?

OPGx-LCA5 delivers a functional copy of the LCA5 gene to retinal cells to restore photoreceptor structure and light-sensing function.

Which clinical programs did Opus Genetics note in the Nov 3, 2025 announcement (IRD)?

The company referenced ongoing Phase 1/2 trials for LCA5 and BEST1 gene therapies and a newly activated clinical site at the Retina Foundation of the Southwest.

Who supported the Good Morning America feature about Opus Genetics (IRD)?

The segment noted support from the Retinal Degeneration Fund and the Foundation Fighting Blindness.

Does the Good Morning America feature report regulatory approval for Opus Genetics' OPGx-LCA5 (IRD)?

No regulatory approvals were reported; the therapy is described as investigational and part of ongoing Phase 1/2 clinical trials.

How can investors watch the Opus Genetics Good Morning America feature mentioned on Nov 3, 2025 (IRD)?

The press release provides a Good Morning America video link to view the full feature.